Koers Eisai Co., Ltd. OTC Markets
Aandelen
ESALY
US2825793092
Farmaceutische producten
Omzet 2025 * | 764 mld. 4,75 mld. 4,39 mld. | Omzet 2026 * | 841 mld. 5,23 mld. 4,83 mld. | Marktkapitalisatie | 1.852 mld. 11,51 mld. 10,63 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2025 * | 45,34 mld. 282 mln. 260 mln. | Nettowinst (verlies) 2026 * | 62,72 mld. 390 mln. 360 mln. | EV/omzet 2025 * | 2,17 x |
Nettoliquiditeiten 2025 * | 195 mld. 1,21 mld. 1,12 mld. | Nettoliquiditeiten 2026 * | 200 mld. 1,25 mld. 1,15 mld. | EV/omzet 2026 * | 1,96 x |
K/w-verhouding 2025 * |
40,8
x | K/w-verhouding 2026 * |
29,5
x | Werknemers | 11.067 |
Dividendrendement 2025 * |
2,49% | Dividendrendement 2026 * |
2,59% | Vrij verhandelbaar | 93,85% |
Recentste transcriptie over Eisai Co., Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01-10-75 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Keisuke Naito
COO | Chief Operating Officer | 35 | 01-10-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01-10-75 |
Fumihiko Ike
BRD | Director/Board Member | 72 | 01-06-21 |
Toru Moriyama
BRD | Director/Board Member | 69 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+56,60% | 809 mld. | |
+39,52% | 624 mld. | |
-7,18% | 351 mld. | |
+7,16% | 289 mld. | |
+13,74% | 240 mld. | |
+13,83% | 220 mld. | |
-0,49% | 219 mld. | |
+8,32% | 166 mld. | |
-2,88% | 157 mld. |